Prognose
Analytikernes gennemsnitlige kursmål er 291,63 € (+0,25 %). Medianen er 291,63 € (+0,25 %).
| Køb |
9 |
| Behold |
13 |
| Sælg |
0 |
Diskussioner i communityet
- Was sind eure aktuellen Top-Aktien-Picks?
Wie die Überschrift schon verrät, würde mich interessieren, welche Aktien ihr aktuell spannend findet. Ziel ist es, ein paar interessante Titel zu entdecken, die ich vielleicht übersehen habe. Ich…
u user_acfe44 IV i Schnack
2 8
Nyheder Til nyhedsfeedet
Penumbra: stroke system Thunderbolt reaches targets in THUNDER study
Penumbra reports that the vacuum thrombectomy system Thunderbolt met the predefined performance goal in the single-arm, multicenter THUNDER study: 87.5% successful reperfusion (mTICI 2b-3). First-pass reperfusion was achieved in 64.8%, mTICI 2c-3 in 70.4%, median time to revascularization was 20 minutes, and complete clot removal was achieved in 83% of cases. Device- or procedure-related serious adverse events occurred in 2.8%, symptomatic intracranial hemorrhage in 0.9%, and 90-day mortality was 11.7%. Thunderbolt recently received FDA approval and the CE mark. » Mere på de.investing.com
Penumbra reaches 52-week high at $328.69
Penumbra shares closed at a new 52-week high of $328.69. The medical device company has a market capitalization of $12.93 billion, a P/E ratio of 75.62 and revenue growth of 17.27% over the past 12 months. For Q4 2025 Penumbra reported revenue of $385.4 million and adjusted EBITDA of $79.1 million, both above analyst expectations, and shareholders approved a merger with Boston Scientific. Analysts differ on the stock’s valuation: InvestingPro rates it as overvalued, UBS remains at “neutral” with a $374 price target, and Evercore ISI raised its target to $360. » Mere på de.investing.com
Penumbra shareholders approve merger with Boston Scientific
Penumbra shareholders voted at a special general meeting to approve the merger agreement with Boston Scientific (28,564,786 yes votes, 85,334 no votes). The deal would make Penumbra a wholly owned subsidiary of Boston Scientific; completion remains subject to regulatory approvals (including Hart‑Scott‑Rodino, antitrust and foreign investment reviews). Penumbra reported Q4 2025 revenue of $385.4 million and adjusted EBITDA of $79.1 million, beating expectations; UBS maintained a "Neutral" rating, and Evercore ISI raised its price target. Additionally, the STORM‑PE study showed improved functional outcomes for vacuum thrombectomy versus pulmonary embolism. » Mere på de.investing.com
Penumbra reaches new all-time high at $352.30 and reports takeover offer from Boston Scientific
Penumbra shares rose to an all-time high of $352.30 after a strong price rally over the past year and a six-month gain of more than 52%. InvestingPro considers the stock overvalued versus fair value, the RSI signals overbought conditions, while the financial position is rated "OUTSTANDING." Penumbra released preliminary Q4 2025 revenue (USD 383.0–384.8 million) and full-year 2025 revenue guidance (approx. USD 1,401–1,403 million). Boston Scientific announced a takeover offer for Penumbra at USD 374 per share, prompting several research houses to cut their ratings to hold/neutral but set price targets at USD 374. » Mere på de.investing.com
Penumbra reports preliminary Q4 revenue growth of over 21%
Medical device maker Penumbra expects preliminary Q4 2025 revenues of $383.0 million to $384.8 million, an increase of about 21.4% to 22.0% year-over-year. Excluding China, growth in the quarter was about 23.2% to 23.8%. For full-year 2025 the company forecasts revenues of $1,401.3 million to $1,403.1 million (growth ~17.3%–17.5%). Preliminary gross margin for Q4 is estimated at 67.9%–68.1%; preliminary operating income for Q4 is $56.9 million–$60.4 million (operating margin 14.8%–15.7%). All figures are preliminary and unaudited; no date was given for the full filings. » Mere på de.investing.com
Virksomhedstal
I det seneste kvartal havde Penumbra Inc en omsætning på 362,1 mio. € og et nettoresultat på 37,33 mio. €
| (EUR) | september 2026 | YoY |
|---|---|---|
| Omsætning | 362,1 mio. | 19,81 % |
| Bruttofortjeneste | 247,47 mio. | 20,79 % |
| Nettoresultat | 37,33 mio. | 4,47 % |
| EBITDA | 54,81 mio. | 16,63 % |
Fundamentale data
| Nøgletal | Værdi |
|---|---|
Markedsværdi | 11,46 mia. € |
Antal aktier | 39,41 mio. |
Højeste/laveste i 52 uger | 330,28 € - 259,69 € |
| Udbytte | Nej |
Beta | 0,69 |
P/E (PE Ratio) | 79,98 |
PEG (PEG Ratio) | -13,56 |
K/I (PB Ratio) | 7,94 |
P/S (PS Ratio) | 8,06 |
Virksomhedsprofil
Penumbra, Inc. designer, udvikler, fremstiller og markedsfører medicinske udstyr i USA og internationalt. Virksomheden tilbyder aspirationsbaserede trombektomisystemer og tilbehørsudstyr, herunder revaskulariseringsudstyr til mekanisk trombektomi, såsom Penumbra System under mærkerne Penumbra RED, JET, ACE, 3D Revascularization Device og Penumbra ENGINE samt komponenter og tilbehør; neurovaskulære embolisationsspiralsystemer til behandling af patienter med aneurismer af forskellig størrelse og andre neurovaskulære læsioner under mærkerne Penumbra Coil 400, POD400, PAC400 og Penumbra SMART Coil; og neurovaskulære adgangssystemer designet til at give intrakranial adgang til brug i en række neurovaskulære behandlinger under mærkerne Neuron, Neuron MAX, Select, BENCHMARK, BMX96, DDC og PX SLIM. Virksomheden leverer desuden neurokirurgiske aspirationsværktøjer til fjernelse af væv og væsker under mærket Artemis Neuro Evacuation Device; aspirationsbaserede trombektomisystemer til vaskulære anvendelser under mærket Indigo System; og løsnelige embolispiralsystemer til perifer embolisation under mærkerne Ruby Coil og Ruby LP. Derudover tilbyder virksomheden mikrokateter til levering af løsnelige spiraler og okklusionsudstyr under mærket LANTERN; og løsnelige, mikrokateter-leverbare okklusionsudstyr primært designet til at okkludere perifere kar under mærket POD (Penumbra Occlusion Device), samt immersive computerbaserede teknologier og immersive terapeutiske løsninger til at fremme sundhed, motorisk funktion og kognition under mærket Real Immersive System; og et supplerende udstyr til brug sammen med Ruby Coil og POD til karokklusion under mærkerne Packing Coil og Packing Coil LP. Virksomheden sælger sine produkter gennem direkte salgsorganisationer og distributører. Penumbra, Inc. blev stiftet i 2004 og har hovedkontor i Alameda, Californien.
| Navn | Penumbra Inc |
| CEO | Adam Elsesser |
| Hjemsted | Alameda,
ca USA |
| Websted | |
| Sektor | Sundhed |
| Branche | Sundhedsudstyr og -produkter |
| Børsnotering | 18.09.2015 |
| Medarbejdere | 4.700 |
Tickersymboler
| Børs | Symbol |
|---|---|
NYSE | PEN |
Frankfurt | 0P8.F |
Düsseldorf | 0P8.DU |
SIX | 0P8.SW |
München | 0P8.MU |